Insider Selling: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Sells $22,828.70 in Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 26,545 shares of the stock in a transaction on Friday, April 12th. The stock was sold at an average price of $0.86, for a total transaction of $22,828.70. Following the transaction, the chief executive officer now owns 129,726 shares in the company, valued at approximately $111,564.36. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jack Phillips also recently made the following trade(s):

• On Wednesday, April 17th, Jack Phillips sold 26,735 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.78, for a total transaction of $20,853.30.
• On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.88, for a total transaction of $13,980.56.
• On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $1.30, for a total transaction of $642.20.

Accelerate Diagnostics Trading Up 11.6 %

NASDAQ:AXDX opened at $0.86 on Friday. The firm has a market capitalization of $18.61 million, a PE ratio of -0.18 and a beta of 0.52. The firm’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $3.16. Accelerate Diagnostics, Inc. has a 1 year low of $0.73 and a 1 year high of $11.90.

Analyst Ratings Changes

A number of research analysts recently issued reports on AXDX shares. Craig Hallum lowered their target price on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating on the stock in a research note on Monday, April 1st. StockNews.com started coverage on shares of Accelerate Diagnostics in a research note on Saturday. They issued a “hold” rating on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Accelerate Diagnostics in a research note on Tuesday, April 2nd.

Institutional Trading of Accelerate Diagnostics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sonora Investment Management Group LLC acquired a new stake in Accelerate Diagnostics in the 3rd quarter worth $63,000. Tejara Capital Ltd bought a new position in shares of Accelerate Diagnostics during the 3rd quarter worth about $78,000. Bank of Montreal Can bought a new position in shares of Accelerate Diagnostics during the 1st quarter worth about $27,000. Cubist Systematic Strategies LLC bought a new position in shares of Accelerate Diagnostics during the 3rd quarter worth about $29,000. Finally, Virtu Financial LLC lifted its holdings in shares of Accelerate Diagnostics by 95.4% during the 4th quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock worth $25,000 after acquiring an additional 17,461 shares during the period. 17.14% of the stock is currently owned by institutional investors and hedge funds.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.